| id,disease_basin,candidate_drug,trial_outcome_summary,failure_mode_evidence,candidate_subgroup_axes,responder_subgroup_signature,non_responder_signature,context_gates,failure_mode_class,salvage_hypothesis,verification_plan,notes,constraints,gold_checklist | |
| FCSC-001,post_viral_crash_basin,"candidate immune modulator","Primary endpoint null; fatigue scale unchanged overall","Subgroup shows improved crash frequency","autonomic tone; PEM severity; viral reactivation markers","High PEM; high crash frequency; elevated reactivation markers","Low PEM; no crash pattern","pacing adherence; infection status","masked responder subgroup","Use in high-PEM subgroup with pacing protocol","Prospective enrichment; crash frequency endpoint","Signal masked by heterogeneity","Under 280 words.","subgroup+gate+class+plan" | |
| FCSC-002,metabolic_insulin_resistance_basin,"candidate appetite agent","Weight loss modest overall; high dropout","Responder signal in high hunger phenotype","baseline hunger; sleep timing; GI tolerance","High hunger; stable sleep schedule; high adherence","Low hunger; irregular sleep; nausea prone","meal timing; dose titration","adherence-gated efficacy","Pair with meal timing protocol; slow titration","Stratify by hunger; track adherence and nausea","Context gate is tolerability","Under 280 words.","subgroup+gate+class+plan" | |
| FCSC-003,autoimmune_flare_basin,"candidate cytokine inhibitor","Flare reduction not significant overall","Benefit only in high flare frequency subgroup","flare frequency; autoantibody load","Flares every 4 weeks; high autoantibody load","Flares rare; low autoantibody load","trigger seasonality; concurrent infections","frequency-gated efficacy","Enroll high-frequency patients; seasonal timing","Enriched trial; flare interval endpoint","Null hides subgroup benefit","Under 280 words.","subgroup+gate+class+plan" | |
| FCSC-004,hyperarousal_basin,"candidate sleep agent","Sleep improves; daytime function worsens","Daytime impairment in slow metabolizers","metabolizer phenotype; baseline fatigue","Fast metabolizers; insomnia dominant","Slow metabolizers; baseline fatigue high","dose timing; occupational demands","toxicity in subgroup","Lower dose or earlier dosing in slow metabolizers","PK stratification; function endpoints","Context is metabolism and schedule","Under 280 words.","subgroup+gate+class+plan" | |
| FCSC-005,fibrotic_progression_basin,"candidate antifibrotic","No significant slope change overall","Responder signal in early-stage imaging subgroup","disease stage; imaging pattern","Early-stage; mild imaging changes","Late-stage; advanced fibrosis","smoking exposure; adherence","stage-gated efficacy","Treat early-stage only with exposure removal","Stage-stratified trial; PFT slope","Early basin escapable","Under 280 words.","subgroup+gate+class+plan" | |
| FCSC-006,chronic_pain_sensitization_basin,"candidate neuromodulator","Pain score improves; high discontinuation","Responders with high threat tone; nonresponders sedated","threat tone; sleep debt; comedication","High threat tone; low sedative burden","High sedative burden; falls risk","comedication; fall risk","contextual antagonism","Use only with sedative deprescribing","Run-in taper; falls endpoint","Context gate is sedation load","Under 280 words.","subgroup+gate+class+plan" | |